Shareholders to Vote on Amended Equity Plan with Significant Annual Evergreen Provision and High Overhang

summarizeSummary

Oric Pharmaceuticals filed its definitive proxy statement for its annual meeting, proposing an amended equity incentive plan that includes a 4% annual evergreen provision without a numerical cap, alongside routine governance matters and executive compensation votes.

check_boxKey Events

• Amended Equity Incentive Plan Proposed

  Shareholders will vote on an amended 2020 Equity Incentive Plan. The plan reduces the annual evergreen share reserve increase from 5% to 4% of outstanding shares but removes the prior numerical cap, allowing for potentially significant ongoing dilution. The plan also eliminates the ability to unilaterally reprice or exchange underwater awards without shareholder approval, a positive governance change.

• High Equity Overhang Reported

  The company reported an equity overhang of 19.1% as of March 31, 2026, indicating a substantial portion of potential future dilution from existing and authorized equity awards.

• Increased Director Compensation

  Non-employee director cash compensation and equity awards have been increased, with initial stock option awards rising from 70,000 to 80,000 shares and annual awards from 35,000 to 40,000 shares, effective after December 17, 2025.

• Executive Compensation and Governance Votes

  Shareholders will cast advisory votes on executive compensation for named executive officers and the frequency of future 'say-on-pay' votes. The board recommends an annual frequency.

auto_awesomeAnalysis

Oric Pharmaceuticals has filed its definitive proxy statement for its upcoming annual meeting, outlining several key proposals for shareholder vote. The most impactful proposal is the amendment and restatement of the 2020 Equity Incentive Plan. While the annual evergreen provision for share reserve increases is being reduced from 5% to 4% of outstanding shares, the critical change is the removal of the previous hard numerical cap. This means the potential annual dilution from the evergreen provision is now tied solely to a percentage of outstanding shares, which, at 4% of the current 103.5 million shares, represents a substantial ongoing dilutive mechanism. The company also reports a high existing overhang of 19.1% as of March 31, 2026. On a positive governance note, the amended plan eliminates the administrator's ability to unilaterally reprice or exchange underwater awards without shareholder approval. Additionally, the company is seeking advisory votes on executive compensation and the frequency of future 'say-on-pay' votes. Non-employee director compensation, including cash retainers and equity awards, has been increased for 2026. This filing follows a period of net insider selling totaling over $700,000 and the company reported a net loss in recent fiscal years, adding to the negative sentiment surrounding the significant potential dilution.